Navigation Links
Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering
Date:1/3/2011

HONG KONG, Jan. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings Limited ("Golden Meditech" or the "Company," together with its subsidiary collectively as the "Group" - 801.HK), Mainland China's leading integrated healthcare enterprise, is pleased to announce that the Company has obtained the approvals from the Taiwan Stock Exchange and the Taiwan Securities and Futures Bureau for its proposed offering and listing of Taiwan Depositary Receipts ("TDR") on the Taiwan Stock Exchange.  The Company will become the first Mainland Chinese healthcare enterprise to list its TDR on the Taiwan Stock Exchange.

The Company intends to offer 90 million TDR units (equivalent to 180 million ordinary Shares of the Company).  A portion of the proceeds will fund the establishment of a representative office in Taiwan.  In view of the rare opportunities arising from the Economic Cooperation Framework Agreement ("ECFA") so as to foster closer ties between industry counterparts on both sides of the Taiwan Strait, the Company is actively pursuing to strengthen its core businesses and market presence through Taiwan's talent advantage.  

According to the Company's recently published interim results in accordance with Hong Kong Accounting Standards, the Group's revenue for the six month ended September 30th, 2010 amounted to HK$163 million with 24% growth relative to the previous corresponding period.  Profit for the period amounted to HK$161 million with 170% growth relative to the previous interim reporting period.

Mr. Kam Yuen, the Company's Chairman and Chief Executive Officer pointed out that the rapid growth of the Group's hospital management business, the penetration of the Autologous Blood Recovery Systems into mid-tier hospitals and the substantial growth in medical accessories consumption all contributed to the increase in the Group's revenue for the period.  The hospital management business accounted for 23% of the Group's total revenue at HK$38million.

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited is China's leading integrated-healthcare device and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx).  Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets over the years, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities.  Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

For enquiries, please contact:

Investor Relations Department

Golden Meditech Holdings Limited

Address:

48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong

Tel: +852-3605-8180

Fax: +852-3605-8181

Email: ir@goldenmeditech.com

Website: www.goldenmeditech.com


'/>"/>
SOURCE Golding Meditech Holdings Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Meditech Announces Annual Results for FY 2009/10
2. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
5. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):